Supernus Pharmaceuticals (SUPN) said Monday the US Food and Drug Administration has cleared a label update for qelbree, a treatment for attention-deficit/hyperactivity disorder, or ADHD.
The updated label describes the drug's "partial agonist activity at the serotonin 5-HT2C receptor and inhibition of the norepinephrine transporter," which highlights the treatment's "multimodal pharmacodynamic profile," the biopharmaceutical company said.
The revised label also includes new lactation data for breastfeeding women with ADHD "showing that the transfer of Qelbree into breastmilk is low," Supernus said.
The drug is approved for use by people ages 6 years and older with ADHD, the company said.
SUPN shares were up 1.8% in early trading.
Price: 38.85, Change: +0.30, Percent Change: +0.78
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.